CTH-301: An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson#s Disease Complicated by Motor Fluctuations (#OFF# Episodes)

Grants and Contracts Details

StatusFinished
Effective start/end date9/23/15 → 5/3/17

Funding

  • Cynapsus Therapeutics Incorporated: $14,331.00